Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr:117:109968.
doi: 10.1016/j.intimp.2023.109968. Epub 2023 Mar 2.

Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2

Negar Firouzabadi  1 , Parisa Ghasemiyeh  2 , Fatemeh Moradishooli  3 , Soliman Mohammadi-Samani  4
Affiliations
Review

Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2

Negar Firouzabadi et al. Int Immunopharmacol. 2023 Apr.

Abstract

It has been more than three years since the first emergence of coronavirus disease 2019 (COVID-19) and millions of lives have been taken to date. Like most pandemics caused by viral infections, massive public vaccination is the most promising approach to cease COVID-19 infection. In this regard, several vaccine platforms including inactivated virus, nucleic acid-based (mRNA and DNA vaccines), adenovirus-based, and protein-based vaccines have been designed and developed for COVID-19 prevention and many of them have received FDA or WHO approval. Fortunately, after global vaccination, the transmission rate, disease severity, and mortality rate of COVID-19 infection have diminished significantly. However, a rapid increase in COVID-19 cases due to the omicron variant in vaccinated countries has raised concerns about the effectiveness of these vaccines. In this review, articles published between January 2020 and January 2023 were reviewed using PubMed, Google Scholar, and Web of Science search engines with appropriate related keywords. The related papers were selected and discussed in detail. The current review mainly focuses on the effectiveness and safety of COVID-19 vaccines against SARS-CoV-2 variants. Along with discussing the available and approved vaccines, characteristics of different variants of COVID-19 have also been discussed in brief. Finally, the currently circulating COVID-19 variant i.e Omicron, along with the effectiveness of available COVID-19 vaccines against these new variants are discussed in detail. In conclusion, based on the available data, administration of newly developed bivalent mRNA COVID-19 vaccines, as booster shots, would be crucial to prevent further circulation of the newly developed variants.

Keywords: COVID-19; SARS-CoV-2 variants; Vaccine coverage; Vaccine effectiveness; Vaccine platforms.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Ciotti M., Ciccozzi M., Terrinoni A., Jiang W.-C., Wang C.-B., Bernardini S. The COVID-19 pandemic. Crit. Rev. Clin. Lab. Sci. 2020;57(6):365–388. - PubMed
    1. Solomon J.J., Heyman B., Ko J.P., Condos R., Lynch D.A. CT of postacute lung complications of COVID-19. Radiology. 2021;301(2):E383–E395. - PMC - PubMed
    1. Gibson P.G., Qin L., Puah S.H. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med. J. Aust. 2020;213(2):54–56. e1. - PMC - PubMed
    1. Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474. - PubMed
    1. Hantoushzadeh S., Norooznezhad A.H. Possible cause of inflammatory storm and septic shock in patients diagnosed with (COVID-19) Arch. Med. Res. 2020;51(4):347–348. - PMC - PubMed

Supplementary concepts